Marshall Wace LLP Has $17.11 Million Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Marshall Wace LLP increased its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 32.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,157 shares of the company's stock after purchasing an additional 37,177 shares during the quarter. Marshall Wace LLP owned about 0.06% of BioNTech worth $17,108,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BNTX. Jones Financial Companies Lllp raised its stake in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after buying an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. grew its holdings in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after acquiring an additional 700 shares during the period. Allianz SE bought a new stake in shares of BioNTech during the 4th quarter valued at $90,000. GAMMA Investing LLC lifted its stake in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after purchasing an additional 300 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of BioNTech in the 4th quarter worth $137,000. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

BNTX has been the topic of several research analyst reports. Morgan Stanley dropped their price objective on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. HC Wainwright dropped their price target on BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Truist Financial began coverage on BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective for the company. BMO Capital Markets raised their target price on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and a consensus price target of $143.44.

BioNTech Stock Performance

Shares of BioNTech stock traded down $18.53 during trading on Friday, reaching $102.01. The company's stock had a trading volume of 6,432,880 shares, compared to its average volume of 970,177. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market cap of $24.48 billion, a PE ratio of -48.58 and a beta of 1.07. The business's 50-day moving average price is $102.14 and its 200-day moving average price is $110.77. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business's revenue for the quarter was down 19.5% on a year-over-year basis. During the same period last year, the firm earned $1.90 earnings per share. Equities analysts forecast that BioNTech SE will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.